COVID-19 preclinical drug development database

Show only projects looking for collaborations
Total Projects:  43
Reset
Phase of project
Type
Modality
Molecular/cellular target
Therapeutic target
Lead institution/organisation
Screening of Targeted Compounds - CVR
MRC - University of Glasgow Centre for Virus Research
Project Type
Repurposing medicines,
Testing existing molecules,
Supporting technologies
Therapeutic target
Preventing infection,
Preventing replication,
Antiviral
Link
Dose selection of therapeutics targeting COVID-19 using the hollow fibre infection model
University of Liverpool
Project Type
Testing existing molecules,
Discovering new molecules,
Supporting technologies
Therapeutic target
Antiviral
Link
Pneumagen - biologics for prevention and treatment of COVID-19
Pneumagen Ltd
Project Type
Testing existing molecules
Therapeutic target
Preventing infection
Link
Preclinical assessment and metabolic activation of the phosphoramidated nucleotide NUC-7738 for repurposing as an anti-SARS-Cov-2 drug.
University of St Andrews
Project Type
Repurposing medicines,
Testing existing molecules
Therapeutic target
Preventing replication
Link
Pre-clinical COVID-19 Drug Discovery
Liverpool School of Tropical Medicine
Project Type
Repurposing medicines,
Testing existing molecules,
Discovering new molecules,
Target validation,
Supporting technologies
Therapeutic target
Preventing infection,
Preventing replication,
Antiviral,
Preventing CRS,
Preventing death
Link
Isolation of SARS-CoV-2 broadly neutralising antibodies
King's College London
Project Type
Discovering new molecules,
Supporting technologies
Therapeutic target
Preventing infection,
Preventing replication,
Antiviral
Link
Exscientia-Diamond-Scripps Partnership
Exscientia
Project Type
Repurposing medicines,
Testing existing molecules,
Discovering new molecules
Therapeutic target
Preventing infection,
Preventing replication,
Antiviral,
Preventing CRS,
Preventing death
Link
Nanobodies
Rosalind Franklin Institute
Project Type
Discovering new molecules,
Supporting technologies
Therapeutic target
Preventing infection,
Preventing replication,
Preventing death
Link
CVR CRUSH: COVID-19 Drug-Screening and Resistance Hub
MRC - University of Glasgow Centre for Virus Research
Project Type
Supporting technologies
Therapeutic target
Link
Novel covalent inhibitors of SARS-CoV-2 main protease
Newcastle University
Project Type
Discovering new molecules
Therapeutic target
Preventing replication,
Antiviral
Link
  • Close

    Phase of project

    AI or in silico design (4)
    High throughput screening (13)
    Focused compound screening (eg. known antiviral compounds) (7)
    Lead optimisation and activity validation (17)
    PK/PD testing and toxicology (5)
    Other (11)
    Close

    Type

    Repurposing medicines (15)
    Testing existing molecules (16)
    Discovering new molecules (21)
    Target validation (11)
    Supporting technologies (15)
    Other (3)
    Close

    Modality

    Small molecule (24)
    Antibody (5)
    Nanobodies or fragments (eg. Fab) (3)
    RNAi (1)
    Fusion protein (2)
    Peptide (4)
    Other (10)
    Close

    Molecular/cellular target

    ACE2 (5)
    IL-6 (2)
    SARS-CoV-2 main protease (5)
    SARS-CoV-2 Spike protein (13)
    Not known (4)
    Other (23)
    Close

    Therapeutic target

    Preventing infection (18)
    Preventing replication (18)
    Antiviral (15)
    Preventing CRS (13)
    Preventing death (8)
    Not known (2)
    Other (5)
    Close

    Lead institution/organisation

    MRC - University of Glasgow Centre for Virus Research (2)
    University of Liverpool (3)
    Pneumagen Ltd (1)
    University of St Andrews (2)
    Liverpool School of Tropical Medicine (1)
    King's College London (5)
    Exscientia (1)
    Rosalind Franklin Institute (1)
    Newcastle University (1)
    University of Huddersfield (2)
    Imperial College London (2)
    University College London (6)
    Royal Free Hospital (1)
    Aston University (2)
    University of Leicester (1)
    University of Roehampton (1)
    EMBL-EBI (1)
    University of Edinburgh (1)
    Institute of Cancer Research (1)
    BerGenBio ASA (1)
    Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast (1)
    Universite de Montreal (1)
    University of Dundee (1)
    RioTech Pharmaceuticals Ltd (1)
    St. George's University of London (1)
    University of Bristol (1)
    University of Southampton (1)